http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
姜鎭馨,朴允仲 충남대학교 대학원 원우회 1969 논문집 Vol.2 No.-
(1) This experiment was conducted to investigate the influence on the cork layer formation along the wounds with sharp knife on the cortex of sweet potato tuber. (2) The dosages of X-ray irradiaton were divided into 750r, 1500r, 3000r and the irradiated sweet potato was stored under the two conditions of temp. of 13-15℃ and temp. of 18-20℃. (3) X-ray irradiation hastened to form the cork layer on the wounded cortex of the sweet potato, especially X-ray irradiation of 3000r was superior to the others. (4) X-ray irradiationof 3000r hastened remarkarbly to form the cork layer the above both conditions, compared with the control. (5) X-ray irradiation of 6000r influenced on the formation of the cork layer as strong as that of 3000r, but it made the layer scattered and rough in the latter period. (6) According to above fact, it is considered that X-ray irradiation of about 3000r is able to apply to the hastening of the cork layer formation on the wounded cortex in the sweet potato.
강진형,Yoo-Lim Kim,Hea-Kyoung Cho,Eun-Sook Lee,Soo Jin Cha,Young Sun Hong,Kyung Shik Lee,구효정 대한암학회 2003 Cancer Research and Treatment Vol.35 No.3
Purpose: Tegafur, an oral prodrug of 5-fluorouracil(5-FU), has been used in the treatment of gastric cancers.UFT (tegafur + uracil) has been developed to enhancethe efficacy of tegafur. This study was conducted to assessthe pharmacokinetics (PK) of tegafur in gastric cancerpatients given the ECU-E regimen (epirubicin, cisplatin,UFT-E, an enteric-coated formula of UFT). A preliminaryevaluation of antitumor efficacy and toxicity ofECU-E regimen was also performed.Materials and Methods: Of the 32 gastric cancer patientsregistered for the ECU-E regimen, 8 participated inthe PK study. The plasma concentration of tegafur wasdetermined using HPLC.Results: Seven out of the 8 patients were evaluable forresponse after 2 cycles, and showed 3 partial responses,1 stable disease and 3 progressive diseases. No majortoxicities were observed. Plasma profiles of the tegafurafter the first dose showed significant differences in theamount and rate of absorption, i.e., rapid absorptiongroup vs. slow absorption group. The level of Cmax in therapid absorption group was 1.8 fold higher, and the AUC0-5h4 fold greater, than those in the slow absorption group,nonetheless, the steady state concentrations showed nosignificant difference. These data indicate that the differentabsorption rates may not affect the overall exposureto tegafur. The patients with low Cpss,peak showed poor efficacycompared to those with high Cpss,peak, suggestingthat the concentration of tegafur may be one of thepharmacodynamic determinants in patients administeredwith ECU-E.Conclusion: This study evaluated the pharmacokineticsof tegafur in gastric patients given the ECU-E regimen,and provides preliminary data on the relationship betweenthe plasma tegafur level and the efficacy, which warrantsfurther evaluation. (Cancer Res Treat. 2003;35:224-231) Purpose: Tegafur, an oral prodrug of 5-fluorouracil (5-FU), has been used in the treatment of gastric cancers.UFT (tegafur + uracil) has been developed to enhance the efficacy of tegafur. This study was conducted to assess the pharmacokinetics (PK) of tegafur in gastric cancer patients given the ECU-E regimen (epirubicin, cisplatin, UFT-E, an enteric-coated formula of UFT). A preliminary evaluation of antitumor efficacy and toxicity of ECU-E regimen was also performed.Materials and Methods: Of the 32 gastric cancer patients registered for the ECU-E regimen, 8 participated in the PK study. The plasma concentration of tegafur was determined using HPLC.Results: Seven out of the 8 patients were evaluable for response after 2 cycles, and showed 3 partial responses, 1 stable disease and 3 progressive diseases. No major toxicities were observed. Plasma profiles of the tegafur after the first dose showed significant differences in the amount and rate of absorption, i.e., rapid absorption group vs. slow absorption group. The level of Cmax in the rapid absorption group was 1.8 fold higher, and the AUC0-5h 4 fold greater, than those in the slow absorption group, nonetheless, the steady state concentrations showed no significant difference. These data indicate that the different absorption rates may not affect the overall exposure to tegafur. The patients with low Cpss,peak showed poor efficacy compared to those with high Cpss,peak, suggesting that the concentration of tegafur may be one of the pharmacodynamic determinants in patients administered with ECU-E.Conclusion: This study evaluated the pharmacokinetics of tegafur in gastric patients given the ECU-E regimen, and provides preliminary data on the relationship between the plasma tegafur level and the efficacy, which warrants further evaluation. (Cancer Res Treat. 2003;35:224-231)
강진형,안명주,김동완,조은경,김주항,신상원,Xin Wang,김종숙,Mauro Orlando,박근칠 대한암학회 2016 Cancer Research and Treatment Vol.48 No.2
Purpose We recently reported on a randomized, open-label, phase 3 trial comparing pemetrexedcisplatin chemotherapy followed by gefitinib maintenance therapy (PC/G) with gefitinib monotherapy in patients with non-small cell lung cancer (NSCLC). Here, we report on a post hoc subgroup analysis of that study assessing the demographics and disposition of the Korean patient subgroup, and comparing the tolerability of PC/G and gefitinib monotherapy and the tumor response with respect to epidermal growth factor receptor (EGFR) status. Materials and Methods Patients, who were ! 18 years, chemonaïve, Korean, light ex-smokers/never-smokers with advanced NSCLC, were randomly assigned (1:1) to PC/G or gefitinib monotherapy. Treatment- emergent adverse events (TEAEs) were graded, and tumor response was measured as change in lesion sum from baseline at best response. The study was registered with ClinicalTrials. gov, NCT01017874. Results Overall, 111 Korean patients were treated (PC/G, 51; gefitinib, 60). Between-arm characteristics were balanced and similar to those of the overall population. Treatment discontinuations due to adverse events were low (PC/G: 1, 2.0%; gefitinib: 7, 11.7%). Overall, 92 patients (82.9%) reported ! 1 TEAE (PC/G, 44; gefitinib, 48); few patients (PC/G, 16; gefitinib, 7) reported severe TEAEs; the most frequent was neutropenia (PC/G arm) and elevated alanine aminotransferase (gefitinib arm). The lesion sum was decreased by PC/G treatment in most patients, regardless of EGFRmutation status, while gefitinib monotherapy reduced the lesion sum in EGFR-positive patients but had no effect in EGFR-negative patients. Conclusion Our results confirm that both PC/G and gefitinib were well tolerated in Korean patients, regardless of EGFR status; however, patients with EGFR wild-type NSCLC may not benefit from gefitinib monotherapy.
강진형,박양태,김효정,김재선 대한췌장담도학회 2022 대한췌담도학회지 Vol.27 No.3
Biliary stent migration is one of the late complications of endoscopic retrograde cholangiopancreatography. Most of the biliary stent migration is asymptomatic and successfully managed by stent removal. A 66-year-old man with unresectable pancreatic cancer, common bile duct obstruction, and duodenal third portion obstruction underwent endoscopic plastic biliary stent placement and duodenal uncovered metallic stent placement in two separate sessions. After 3 weeks from the duodenal stenting, he presented with hematemesis. Urgent esophagogastroduodenoscopy and magnetic resonance imaging showed hemobilia. The patient recovered with conservative managements. Cross-sectional imagings done 2 months later demonstrated the penetration of the biliary stent into portal vein. Here, we present a case of delayed hemobilia caused by penetration of biliary plastic stent into the portal vein.